Free tool
FAERS Monitor: Atelvia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022560 or its brand name (Atelvia, Risedronate Sodium). Reports on generic versions are filed under their own applications.
Reports
13,245
Serious
11,961
90% of reports
Hospitalization
5,596
Death reported
1,836
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain2,586
- drug ineffective2,547
- off label use2,520
- vomiting2,310
- drug hypersensitivity2,305
- dyspnoea2,272
- arthralgia2,259
- pneumonia2,083
- fatigue1,975
- rheumatoid arthritis1,904
- wheezing1,886
- asthma1,857
- nausea1,823
- malaise1,802
- diarrhoea1,791
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 228 |
| 2005 | 261 |
| 2006 | 138 |
| 2007 | 247 |
| 2008 | 316 |
| 2009 | 217 |
| 2010 | 169 |
| 2011 | 220 |
| 2012 | 313 |
| 2013 | 168 |
| 2014 | 136 |
| 2015 | 207 |
| 2016 | 286 |
| 2017 | 196 |
| 2018 | 315 |
| 2019 | 524 |
| 2020 | 1,019 |
| 2021 | 1,143 |
| 2022 | 1,435 |
| 2023 | 1,435 |
| 2024 | 1,666 |
| 2025 | 1,640 |
| 2026 | 966 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,914 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wheezingSignal | 1,886 | 52.1 | 50.0 | 91,781 |
| rheumatoid arthritisSignal | 1,904 | 27.1 | 26.0 | 47,230 |
| asthmaSignal | 1,857 | 26.5 | 25.4 | 45,057 |
| drug hypersensitivitySignal | 2,305 | 19.1 | 18.4 | 39,479 |
| pneumoniaSignal | 2,083 | 10.3 | 9.9 | 17,592 |
| arthralgiaSignal | 2,259 | 8.7 | 8.3 | 15,543 |
| vomitingSignal | 2,310 | 7.8 | 7.5 | 14,014 |
| painSignal | 2,586 | 6.7 | 6.5 | 12,881 |
| malaiseSignal | 1,802 | 6.5 | 6.3 | 8,609 |
| dyspnoeaSignal | 2,272 | 6.4 | 6.2 | 10,579 |
| off label useSignal | 2,520 | 4.6 | 4.4 | 7,334 |
| diarrhoeaSignal | 1,791 | 4.4 | 4.2 | 4,865 |
| fatigueSignal | 1,975 | 4.0 | 3.9 | 4,669 |
| nauseaSignal | 1,823 | 3.7 | 3.5 | 3,658 |
| drug ineffectiveSignal | 2,547 | 3.1 | 3.0 | 3,790 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.